Foot on the pedal for Predictive Oncology

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Pamela Bush, Chief Business Officer at Predictive Oncology. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pam, covering: The key aspects to successful deal-making learned over a decade with Eli Lily How a passion for curing cancer led Pamela to an opportunity to impact thousands of promising candidates directly How active machine learning is being used to screen molecules, help companies fail fast, and increase the success of a molecule in clinical trials The challenge of selling a disruptive, game-changing platform that could become a vital decision tool in the future Pamela Bush, Ph.D. has over twenty years of experience in venture creation, finance, and business development in the life sciences industry. Pamela is the Chief Business Officer for Predictive Oncology where she leads the strategy and business development activities across the portfolio. Prior to joining Predictive Oncology, Pamela worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. In addition to her Lilly work experience, Pamela has worked in economic development, academia, and business consulting supporting the creation and growth of 100+ life sciences start-ups. Pamela holds a Ph.D. in Molecular Genetics and an MBA from Carnegie Mellon University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.